Boston Scientific Forecasts Q4 2024 Adjusted EPS Of $0.64-$0.66 Versus Consensus Of $0.64
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific projects Q4 2024 adjusted EPS of $0.64-$0.66, aligning with consensus estimates. The company anticipates net sales growth of 16.5-18.5% on a reported basis and 14-16% organically, excluding currency and acquisition impacts.
October 23, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's Q4 2024 adjusted EPS forecast of $0.64-$0.66 aligns with consensus, indicating stable performance. Expected net sales growth of 16.5-18.5% reported and 14-16% organic suggests strong revenue momentum.
The alignment of Boston Scientific's adjusted EPS forecast with consensus suggests market expectations are met, which is generally positive for stock sentiment. The strong projected net sales growth further supports a positive outlook, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100